News
STAY TUNED: ELIXI NEWS FROM THE WORLD
It’s Rare disease day!
28 February 2023
300 million people worldwide are living with a rare disease and today it is RARE DISEASE DAY. We, at Elixi, want to participate in raising awareness and generating change for the millions of people living with a rare disease, their families and carers. Today, we want to join this…
Welcome to our new Export Manager, Federica!
17 February 2023
We are overly excited to welcome our new Export Manager, Federica Davitti, into the Elixi team! Federica has more than 20 years of experience in the pharmaceutical industry and will bring her huge expertise and knowledge to the team! Good luck Federica!…
Find Elixi at Arab Health!
3 February 2023
Thank you Arab Health!!!! we had a blast!!! #teamspirit #arabhealth https://www.linkedin.com/feed/update/urn:li:activity:7027248432746508288
Fabio Macchi is our new Head of Medical and Quality Departments.
16 January 2023
We are extremely proud and excited to announce the latest addition to our " dream team" at Elixi! Fabio Macchi has recently joined as Head of Medical and Quality Departments. With a background in Biochemistry, Biotechnology and Quality Assurance, Fabio brings almost 30 years of experience in…
Carvykti (ciltacabtagene autoleucel), new gene therapy to treat adult patients with multiple myeloma
30 March 2022
EMA has recommended a conditional marketing authorisation in the European Union (EU) for Carvykti (ciltacabtagene autoleucel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies and whose cancer has worsened since they…
Jardiance (empagliflozin)approved for Wider Range of Patients with Heart Failure
11 March 2022
The U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults. Jardiance was originally approved by the FDA in 2014 as a supplement to diet and exercise to improve glucose control in adults with…
Kimmtrak (tebentafusp), a monotherapy for the treatment of adult patients with uveal melanoma, a rare type of eye cancer.
9 March 2022
EMA has recommended granting a marketing authorisation in the European Union (EU) for Kimmtrak (tebentafusp), a monotherapy for the treatment of adult patients with uveal melanoma, a rare type of eye cancer. Uveal melanoma is a rare and aggressive disease in which cancer cells form in the tissues…
Breyanzi (lisocabtagene maraleucel) New gene therapy treatment for patients with relapsed or refractory large B-cell lymphoma
7 February 2022
EMA has recommended granting a marketing authorisation in the EU for Breyanzi (lisocabtagene maraleucel), a gene therapy for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), whose…
Cyltezo(adalimumab-adbm), the First Interchangeable Biosimilar to Humira
3 November 2021
The US FDA has approved the first interchangeable biosimilar product to treat certain inflammatory diseases. Cyltezo (adalimumab-adbm), originally approved in August 2017, is both biosimilar to, and interchangeable with (may be substituted for), its reference product Humira (adalimumab) for…